SRR10900595
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.500
- MTORC1_SIGNALING+0.400
- MYC_TARGETS_V1+0.400
- GLYCOLYSIS+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- PROTEIN_SECRETION+0.300
- SPERMATOGENESIS+0.300
- ANDROGEN_RESPONSE+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.700
- INTERFERON_GAMMA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- APICAL_JUNCTION-0.300
- COMPLEMENT-0.300
- IL2_STAT5_SIGNALING-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.300
- MYOGENESIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1195 | — | — | 0.869 |
| 2 | SRR5088861 | — | — | 0.856 |
| 3 | MDT-AP-2956 | Med | Medulloblastoma | 0.856 |
| 4 | R130 | — | — | 0.852 |
| 5 | BS_KDSTG5YY | Posterior Fossa Ependymoma | — | 0.844 |
| 6 | TCGA-BT-A0S7-01A-11R-A10U-07 | — | — | 0.842 |
| 7 | X7c81e3d9.c538.468a.8a2a.f34513bac230 | — | cohortA3 | 0.842 |
| 8 | BS_KDSTG5YY | EPN | Posterior Fossa EPN | 0.840 |
| 9 | SJEPD030795_D3.RNA-Seq | EPN | Posterior Fossa EPN | 0.838 |
| 10 | TCGA-OR-A5LE-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |